Rigosertib

Mechanism of Action: Rigosertib is useful for customers examining how signaling disruption affects protein stability and degradation sensitivity. By perturbing Ras-effector interactions, mitotic signaling, and phosphorylation-dependent networks, it can help evaluate whether pathway remodeling promotes destabilization or turnover of selected signaling proteins.

• PROTAC-Mediated Rigosertib Degradation: Rigosertib can be leveraged as a warhead in PROTACs to recruit an E3 ligase and drive selective degradation of its intended kinase targets. This application supports mapping degradation potency versus occupancy, optimizing linker length and geometry, and distinguishing true degradation phenotypes from transient inhibition in pathway readouts.

• Kinase Pathway Target Validation: Use Rigosertib-based PROTAC constructs to interrogate kinase network dependencies by comparing degradation-driven signaling changes to inhibitor-only controls. This direction enables systematic evaluation of downstream phosphorylation dynamics, cell-cycle effects, and compensatory responses, helping identify which kinase nodes are most effectively eliminated through targeted proteolysis.

• Structure-Guided PROTAC Optimization: Rigosertib’s binding mode can inform structure-guided PROTAC design to enhance ternary complex formation and improve degradation efficiency. Researchers can vary attachment sites and linker composition to increase productive engagement, then quantify degradation kinetics, dose–response relationships, and selectivity across related kinases.

• Mechanism of Action Dissection: Rigosertib PROTACs can be used to separate catalytic inhibition effects from proteasome-dependent target removal. By monitoring target turnover, ubiquitination, and rescue with proteasome or neddylation pathway perturbations, experiments can clarify whether observed phenotypes arise from degradation magnitude, residence time, or off-target engagement.

Structure: The structure of Rigosertib is characterized by carboxylic acid or carboxylate handle; amide/urea/sulfonamide hydrogen-bonding motifs. These features provide defined hydrogen-bonding, hydrophobic, and steric elements that can support affinity retention while enabling analogue-based linker-vector selection.

Reactivity: The acid handle supports amide coupling with amino-PEG, alkyl-diamine, piperazine, or aminoalkyl E3-ligase ligands. For PROTAC construction, the POI ligand can be paired with CRBN ligands such as thalidomide, pomalidomide, or lenalidomide analogues, VHL ligands such as VH032 derivatives, or less common IAP/MDM2/cIAP-recruiting ligands, with alkyl, PEG, piperazine, triazole, or amide linkers screened for ternary-complex formation. In practice, incorporation into PROTACs should begin from derivatives that preserve the reported binding pharmacophore, followed by systematic variation of linker length, polarity, rigidity, and exit-vector geometry to optimize target engagement, E3 recruitment, and cellular degradation readouts.